Casi Pharmaceuticals is UNDERVALUED at 2.96 per share with modest projections ahead.
We provide trade advice to complement the prevailing
expert consensus on Casi Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of CASI Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with CASI Pharmaceuticals this year
Annual and quarterly reports issued by CASI Pharmaceuticals are formal
financial statements that are published yearly and quarterly and sent to CASI stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as CASI Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
CASI Pharmaceuticals Gross Profit
CASI Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing CASI Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show CASI Pharmaceuticals Gross Profit growth over the last 10 years. Please check CASI Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
Is Casi Pharmaceuticals a risky opportunity?
Let's check the volatility. Casi Pharmaceuticals is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Casi Pharmaceuticals (NASDAQ:CASI) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Casi Pharmaceuticals stock makes you a part-owner of that company.
Casi Pharmaceuticals Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Casi Pharmaceuticals. The Casi Pharmaceuticals consensus assessment is calculated by taking the average estimates from all of the analysts covering Casi Pharmaceuticals
| Strong Buy | 4 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Does Casi Pharmaceuticals have anything more to lay out in August?
Current expected short fall is at -5.51. Casi Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Casi Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Casi Pharmaceuticals volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Casi Pharmaceuticals' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Casi Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Casi Pharmaceuticals Implied Volatility
Our Final Perspective on Casi Pharmaceuticals
While few other entities in the biotechnology industry are either recovering or due for a correction, Casi Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 12th of August 2022, we believe that at this point, Casi Pharmaceuticals is dangerous with
very low odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be
undervalued. Our primary 90 days 'Buy-Sell' recommendation on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of CASI Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
